# IGC Pharma, Inc.: Form 10-Q for the period ended Dec 31, 2015

- Company: [IGC Pharma, Inc.](/companies/igc.md) (CIK 1326205)
- Form: 10-Q
- Filed: 2016-02-16
- Accepted by EDGAR: Feb 16, 2016, 16:10 ET
- Period: 2015-12-31
- Accession: 0001185185-16-003719
- Inline XBRL: yes
- Main document: https://www.sec.gov/Archives/edgar/data/1326205/000118518516003719/indiaglobalization10q123115.htm
- All documents and exhibits: https://www.sec.gov/Archives/edgar/data/1326205/000118518516003719/

## Figures reported in this filing

Standardized XBRL line items for the period ended 2015-12-31.

| Line item | Period | Value | XBRL concept |
| --- | --- | ---: | --- |
| Revenue | 3 months, 2015-10-01 to 2015-12-31 | $1.1m | us-gaap:Revenues |
| Revenue | 9 months, 2015-04-01 to 2015-12-31 | $5.0m | us-gaap:Revenues |
| Cost of revenue | 3 months, 2015-10-01 to 2015-12-31 | $878.9k | us-gaap:CostOfRevenue |
| Cost of revenue | 9 months, 2015-04-01 to 2015-12-31 | $4.4m | us-gaap:CostOfRevenue |
| Selling, general and administrative | 3 months, 2015-10-01 to 2015-12-31 | $437.7k | us-gaap:SellingGeneralAndAdministrativeExpense |
| Selling, general and administrative | 9 months, 2015-04-01 to 2015-12-31 | $1.3m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Operating income | 3 months, 2015-10-01 to 2015-12-31 | −$374.9k | us-gaap:OperatingIncomeLoss |
| Operating income | 9 months, 2015-04-01 to 2015-12-31 | −$1.1m | us-gaap:OperatingIncomeLoss |
| Interest expense | 3 months, 2015-10-01 to 2015-12-31 | $50.8k | us-gaap:InterestExpense |
| Interest expense | 9 months, 2015-04-01 to 2015-12-31 | $179.5k | us-gaap:InterestExpense |
| Income tax | 3 months, 2015-10-01 to 2015-12-31 | $0 | us-gaap:IncomeTaxExpenseBenefit |
| Income tax | 9 months, 2015-04-01 to 2015-12-31 | $0 | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months, 2015-10-01 to 2015-12-31 | −$402.7k | us-gaap:NetIncomeLoss |
| Net income | 9 months, 2015-04-01 to 2015-12-31 | −$1.4m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months, 2015-10-01 to 2015-12-31 | −$0.02 | us-gaap:EarningsPerShareDiluted |
| Diluted EPS | 9 months, 2015-04-01 to 2015-12-31 | −$0.09 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months, 2015-10-01 to 2015-12-31 | −$0.02 | us-gaap:EarningsPerShareBasic |
| Basic EPS | 9 months, 2015-04-01 to 2015-12-31 | −$0.09 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months, 2015-10-01 to 2015-12-31 | 16,224,906 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Diluted shares (weighted) | 9 months, 2015-04-01 to 2015-12-31 | 16,224,906 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 9 months, 2015-04-01 to 2015-12-31 | $3.3k | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 9 months, 2015-04-01 to 2015-12-31 | $806 | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Cash and equivalents | at 2015-12-31 | $607.6k | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | at 2015-12-31 | $3.4m | us-gaap:AssetsCurrent |
| Total assets | at 2015-12-31 | $18.4m | us-gaap:Assets |
| Current liabilities | at 2015-12-31 | $1.3m | us-gaap:LiabilitiesCurrent |
| Total liabilities | at 2015-12-31 | $4.7m | us-gaap:Liabilities |
| Long-term debt | at 2015-12-31 | $648.1k | us-gaap:LongTermDebtNoncurrent |
| Short-term borrowings | at 2015-12-31 | $538.4k | us-gaap:ShortTermBorrowings |
| Shareholders' equity | at 2015-12-31 | $13.1m | us-gaap:StockholdersEquity |

## Management's discussion and analysis

As filed, 19,714 characters.

The following discussion and analysis of our financial condition and results of operations should be read in conjunction with our unaudited condensed financial statements and related notes that appear elsewhere in this Quarterly Report on Form 10-Q, and the Annual Report on Form 10-K filed with the SEC on July 13, 2015. In addition to historical consolidated financial information, the following discussion contains forward-looking statements that reflect our plans, estimates and beliefs. Our actual results could differ materially from those discussed in the forward-looking statements. Factors that could cause or contribute to these differences include those discussed in our Annual Report on Form 10-K filed with the SEC on July 13, 2015, including the risk factors set out in Item 1A therein. Therefore, the financial statements included in this Report should be read in conjunction with the audited Consolidated Financial Statements contained in the Company’s Annual Report on Form 10-K filed with the SEC on July 13, 2015.

### Company Overview

India Globalization Capital, Inc. (“IGC”), a Maryland corporation, was organized on April 29, 2005 as a blank check company formed for the purpose of acquiring one or more businesses with operations primarily in India, and now Hong Kong and China, through a merger, capital stock exchange, asset acquisition or other similar business combination or acquisition. On March 8, 2006, the Company completed an initial public offering. Currently, IGC is in the process of positioning itself in one of the world’s fastest growing industries -- phytocannabinoid-based biopharmaceuticals. In the United States, we develop phytocannabinoid-based therapies for the treatment of a wide range of conditions that are life altering or life threatening; we also build state-of-the art facilities that can be used to grow and extract pharmaceutical grade phytocannabinoids. Long term, we expect to position the company to be a leading provider of cannabinoid based Active Pharmaceutical Ingredients (“API”). As part of our legacy businesses, in India, we engage in leasing equipment to the construction and other industries, and in Hong Kong, through a subsidiary, we run a trading company. In China we hold iron ore mining assets, that we are considering selling. It is our intent, to over time, divest of these businesses and assets and focus on building cash flowing businesses with a significantly smaller and manageable international geographic footprint. In order to achieve this we expect to extricate ourselves from certain existing geographic areas and, through either organic growth or through acquisitions, expand or enter new ones where we can build scale.

Phytocannabinoids are chemical compounds that exert a range of effects on the human body including, impacting the immune response, gastrointestinal maintenance and motility, muscle functioning, and nervous system response and functioning. Since September, 2014, we have filed several provisional patents with the United States Patent and Trademark Office (“USPTO”) in the combination therapy space for the indications of pain, medical refractory epilepsy and cachexia as part of our intellectual property strategy focused on the health care industry. In September 2015, the U.S. Patent & Trademark Office notified IGC that its provisional patent application (Prov.62/050,864) based on a novel therapy that uses cannabinoid extracts for the treatment of pain was converted (PCT/US2015/050342), internally formulation IGC501. IGC is currently developing a nationwide brand by using this formulation as an anchor for the treatment of debilitating pain with administration via a topical cream. We intend to file the respective non-provisional patent applications within 12 months of the provisional patent applications. There is no guarantee that filing a provisional or a non-provisional patent application will result in a successful registration with the USPTO. We are also working on additional patent applications to keep building an intellectual property portfolio that will allow us to pursue our short, medium and long-term business strategies.

Our short-term plan is to become profitable by 1) building and leasing leading edge facilities that can be eventually be used to grow and extract pharmaceutical grade phytocannabinoids, 2) divesting un-profitable businesses and acquiring complementary businesses and assets and 3) developing, testing and filing patent phytocannabinoid based therapies. Our long-term plan, based almost entirely on the developing federal regulations, is to position IGC as a leading provider of phytocannabinoid based Active Pharmaceutical Ingredients.

Our principal executive offices are located at 4336 Montgomery Avenue, Bethesda, Maryland 20814, and our telephone number is (301) 983-0998. We maintain a website at www.igcinc.us. The information contained on our website is not incorporated by reference in this report, and you should not consider it a part of this report.

### Subsidiaries Overview

HK Ironman is a Hong Kong-based company incorporated on December 20, 2010 to acquire PRC Ironman. PRC Ironman was incorporated as Linxi Hefei Economic & Trade Co., Ltd. in China on January 8, 2008. HK Ironman owns 95% of PRC Ironman. PRC Ironman is engaged in the processing of iron ore from sand and dirt at its beneficiation plants in southwest Linxi in the autonomous region of eastern Inner Mongolia. On February 2, 2015, IGC filed a lawsuit for the cancellation of shares that were issued to the shareholders of HK Ironman. The lawsuit is in the preliminary stages and is expected to settle by fiscal year 2017.

Incorporated on February 19, 2007, India Globalization Capital, Mauritius, Limited (IGC-M) is a Mauritius based company that manages and owns all the subsidiaries based in India: IGC Materials, Private Limited (“IGC-MPL”), IGC Logistics, Private Limited (“IGC-LPL”), IGC India Mining and Trading (“IGC-IMT”) and Techni Bharathi Limited (“TBL”). TBL was incorporated on June 19, 1982, in Cochin, India. TBL is an engineering and construction company currently focused on the heavy equipment leasing business. TBL has a focus in the Indian states of Kerala, Karnataka, and Tamil Nadu. On March 31, 2013, TBL became a fully-owned subsidiary of IGC. The other Indian subsidiaries are focused on the trading of materials such as iron ore to customers in India and China.

On January 21, 2013, we incorporated IGC HK Mining and Trading Limited (“IGC-HK”) in Hong Kong. In September 2014, we changed the subsidiary’s name to IGC Cleantech (“IGC-CT”). IGC-CT is a wholly-owned subsidiary of IGC-Mauritius and is not currently an operational subsidiary.

On May 31, 2014, IGC completed the acquisition of 51% of the issued and outstanding share capital of Golden Gate Electronics Limited, a corporation organized and existing under the laws of Hong Kong (formerly "Golden Gate"). This subsidiary, now known as IGC International Limited (“IGC-INT”), operates an e-commerce platform for trading of commodities and electronic components.

On June 27, 2014, we entered into an agreement with TerraSphere Systems LLC to develop multiple facilities to produce organic leafy green vegetables utilizing TerraSphere’s advanced pesticide-free organic indoor farming technology. Under the agreement, we will own 51% of each venture once production is operational, and will have a right of first refusal to participate in all future build-outs. IGC is in the process of negotiating a return of the $150,000 advance.

On December 18, 2014, IGC entered into a Purchase Agreement with Apogee the previous sole owner of the outstanding membership interests of Midtown Partners & Co., LLC, a Florida limited liability company registered as a broker-dealer under the Securities Exchange Act of 1934 (“Midtown”), and acquired, in an initial closing, 24.9% of the outstanding membership interests in Midtown. In consideration of the initial membership interests, we have to issue to Apogee 1,200,000 shares of our common stock (subject to downward adjustment based on certain Q4 2014 financial statement matters). Following the receipt of all required SEC, FINRA and other regulatory approvals, we have agreed to acquire, in a final closing, the remaining 75.1% of the outstanding membership interests in Midtown in consideration of our issuance to Apogee of an additional 700,000 shares of our common stock (subject to downward adjustment based on certain financial statement matters prior to the final closing). As of June 30, 2015, Apogee and Midtown Partners had not received the requisite approvals from FINRA. As a result, pursuant to the terms of the Agreement, there are several penalties that will apply, including the cancellation of 700,000 shares of IGC stock and a penalty of $125,000 payable by Apogee to IGC. The parties are in the process of negotiating a settlement.

### Results of Operations

### Three Months ended December 31, 2015 Compared to Three Months ended December 31, 2014

*Revenue -* Total revenue was $1,084,651 for the three months ended December 31, 2015 as compared to $2,542,192 for the three months ended December 31, 2014. In the three-month periods ended December 31, 2015 and 2014, the revenue was primarily generated by the trading of electronics and rental of heavy equipment. The revenue decreased because we cut back on low margin trading activity. Given the slowdown in China and the global economies, our visibility into the trading business is diminished. We are beginning to see longer payment cycles, lower margins, decreased order flows and several larger companies in this space closing down. Our management is concerned and cognizant about the risk and credit exposure to our balance sheet and has made protecting it one of our highest priorities.

*Cost of Revenue (excluding depreciation) –* Cost of revenue for the three months ended December 31, 2015 was $878,858 as compared to $2,343,062 for the three months ended December 31, 2014. The cost of revenue decreased because of decreased revenue.

*Selling, General and Administrative* - Selling, general and administrative expenses were $437,717 for the three months ended December 31, 2015 as compared to $544,551 for the three months ended December 31, 2014. The SG&A includes $115,254 of non-cash expenses associated with ESOP and $122,598 on research and development associated with our phytocannabinoid based therapies and the filing of associated patents. The overall decrease in SG&A also reflects cutting of costs related to the legacy mining business.

*Depreciation –* The depreciation expense was approximately $142,945 in the three months ended December 31, 2015 as compared to $153,725 in the three months ended December 31, 2014. The depreciation is largely from our mining assets.

*Interest and other financial expenses –* The interest expense and other financial expenses for the three months ended December 31, 2015 were approximately $50,819 as compared to approximately $61,957 for the three months ended December 31, 2014. The interest expense includes $13,154 in non-cash interest paid on the outstanding Notes Payable.

*Other income/(loss) –* Other income loss for the three-month period ended December 31, 2015 contains certain foreign exchange gain/(loss) arising on account of re-measurement of certain intercompany receivables between the US holding company and the foreign subsidiaries. The total foreign exchange loss for the three-month periods ended December 31, 2015 and 2014 amounted to $23,532 and $43,418, respectively, and for the nine-month periods ended December 31, 2015 and 2014 amounted to $139,657 and $121,473 respectively.

*Consolidated Net Income/(loss) –* In the three months ended December 31, 2015, the Company reported a GAAP net income loss of $402,684 and a GAAP EPS loss of $0.02 compared to a GAAP net income loss of $590,114 and a GAAP EPS loss of $0.05 for the three months ended December 31, 2014. Management’s short term objective is to become profitable either through organic growth or through acquisitions.

### Nine Months Ended December 31, 2015 Compared to Nine Months Ended December 31, 2014

*Revenue -* Total revenue was approximately $4,999,045 for the nine months ended December 31, 2015, as compared to about $5,423,872 for the nine months ended December 31, 2014. The slowdown of global economies including China is impacting our business as we are beginning to see slower order flow, lower margins, and larger companies downsizing and exiting the market.

*Cost of Revenue (excluding depreciation) –* Cost of revenue for the nine months ended December 31, 2015 was approximately $4,423,226 as compared to approximately $4,966,863 for the nine months ended December 31, 2014.

*Selling, General and Administrative* - Selling, general and administrative expenses were about $1,268,474 for the nine months ended December 31, 2015 as compared to approximately $2,413,665 for the nine months ended December 31, 2014. The overall decrease in SG&A reflects cost cutting associated from our mining business.

*Depreciation –* The depreciation expense was approximately $447,774 in the nine months ended December 31, 2015 as compared to about $457,768 in the nine months ended December 31, 2014.

*Interest and other financial expenses –* The interest expense and other financial expenses for the nine months ended December 31, 2015 were about $179,502 as compared to approximately $202,876 for the nine months ended December 31, 2014.

*Other income/(loss) –* The total foreign exchange loss for the nine-month period ended December 31, 2015 and December 31, 2014 is $139,657 and $121,473, respectively.

*Consolidated Net Income/ (loss) –* Consolidated net loss for the nine months ended December 31, 2015 was approximately $1,384,547 compared to a consolidated net loss of about $2,695,520 for the nine months ended December 31, 2014.

### Off-Balance Sheet Arrangements

We do not have any undisclosed investments in special purpose entities or undisclosed borrowings or debt.

### Liquidity and Capital Resources

This liquidity and capital resources discussion compares the consolidated company financial position for the nine-month periods ended December 31, 2015 and 2014.

During the nine months ended December 31, 2015, cash provided in operating activities was $3,253, as compared to $2,127,597 used during the nine months ended December 31, 2014.

During the nine months ended December 31, 2015, $35,271 cash was provided by investing activities from continuing operations as compared to $716,857 used during the same period in 2014.

During the nine months ended December 31, 2015, net cash used in financing activities was $267,060 as compared to $2,822,032 provided during the same period in 2014.

For the quarter ended December 31, 2015, our non-GAAP cash burn was approximately $107,800 after adjusting for $142,945 of depreciation, $23,532 of non-cash foreign exchange loss, $13,154 of non-cash interest and $112,254 stock issuance related expenses.

At the end of December 31, 2015, our cash and cash equivalents along with restricted cash was $607,636 and working capital of $2,160,758 as against $2,029,848 on March 31, 2015. While we have sufficient cash to continue business operations with limited expansion, we expect to raise capital in the coming quarters in order to accelerate our development of phytocannabinoid therapies and the building of infrastructure for growing plant based medical grade active pharmaceutical ingredients. Our short term goal is to become profitable either organically or through acquisitions, and our long term goal is to become the leading provider of phytocannabinoid based APIs.

### Critical Accounting Policies

See Note 2 - Significant Accounting Policies of the Notes to Consolidated Financial Statements in Part I, Item 1 of this report for a discussion of our critical accounting policies.

### Forward-Looking Statements

The Private Securities Litigation Reform Act of 1995 provides a safe harbor for forward-looking statements. This report and the documents incorporated in this report by reference contain “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended (the “Securities Act”) and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). Additionally, we or our representatives may, from time to time, make other written or verbal forward-looking statements. In this report and the documents incorporated by reference, we discuss plans, expectations and objectives regarding our business, financial condition and results of operations. Without limiting the foregoing, statements that are in the future tense, and all statements accompanied by terms such as “believe,” “project,” “expect,” “trend,” “estimate,” “forecast,” “assume,” “intend,” “plan,” “target,” “anticipate,” “outlook,” “preliminary,” “will likely result,” “will continue” and variations of them and similar terms are intended to be “forward-looking statements” as defined by federal securities laws. We caution you not to place undue reliance on forward-looking statements, which are based upon assumptions, expectations, plans and projections. Forward-looking statements are subject to risks and uncertainties, including those identified in the “Risk Factors” included in the Company’s Annual report on Form 10-K and in the documents incorporated by reference that may cause actual results to differ materially from those expressed or implied in the forward-looking statements. Forward-looking statements speak only as of the date when they are made. Except as required by federal securities law, we do not undertake any obligation to update forward-looking statements to reflect events, circumstances, changes in expectations or the occurrence of unanticipated events after the date of those statements. We intend that all forward-looking statements made will be subject to safe harbor protection of the federal securities laws pursuant to Section 27A of the Securities Act and Section 21E of the Exchange Act.

Forward-looking statements are based upon, among other things, our assumptions with respect to:

- competition in exploiting phytocannabinoids for pharmaceutical and nutraceutical applications;
- federal and state legislation for regulating phytocannabinoids;
- public and regulatory reaction to the use of phytocannabinoids;
- our ability to build facilities that can eventually be used by us to produce pharmaceutical grade phytocannabinoids;
- our ability to obtain and protect patents for the use of phytocannabinoids;
- our ability to win licenses, contracts and execute on them;
- current and future economic and political conditions especially in Asia;
- overall industry and market performance;
- the impact of accounting pronouncements;
- management’s goals and plans for future operations; and
- other assumptions described in this filing underlying or relating to any forward-looking statements.

You should consider the limitations on, and risks associated with, forward-looking statements and not unduly rely on the accuracy of predictions contained in such forward-looking statements. As noted above, these forward-looking statements speak only as of the date when they are made. Moreover, in the future, we may make forward-looking statements through our senior management that involve the risk factors and other matters described in the Company’s Annual report on Form 10-K, as well as other risk factors subsequently identified, including, among others, those identified in our filings with the SEC in our quarterly reports on Form 10-Q and our current reports on Form 8-K.

## Market risk

As filed, 159 characters.

Pursuant to Item 305(e) of Regulation S-K, the Company is not required to provide the information required by this Item as it is a “smaller reporting company.”

## Controls and procedures

As filed, 1,774 characters.

### Evaluation of Disclosure Controls and Procedures

As of the end of the period covered by this report, management conducted an evaluation, under the supervision and with the participation of its Chief Executive Officer (CEO) and its principal financial and accounting officer (PFAO), of the effectiveness of the design and operation of our disclosure controls and procedures pursuant to Rules 13a-15 and 15d-15 of the Securities Exchange Act of 1934. Based upon that evaluation, our CEO and PFAO concluded that our disclosure controls and procedures are effective.

Disclosure controls and procedures are defined by Rules 13a-15(e) and 15d-15(e) of the Exchange Act as controls and other procedures that are designed to ensure that information required to be disclosed by us in reports filed with the SEC under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by us in reports filed under the Exchange Act is accumulated and communicated to our management, including our CEO and PFAO, or persons performing similar functions, as appropriate, to allow timely decisions regarding required disclosure.

### Changes in Internal Control over Financial Reporting

There were no changes in our internal controls over financial reporting during our fiscal quarter ended December 31, 2015 which were identified in conjunction with Management’s evaluation required by paragraph (d) of Rule 13a-15 and 15d-15 under the Exchange Act that have materially affected, or are reasonably likely to materially affect, our internal controls over financial reporting.

## Risk factors

As filed, 1,228 characters.

The risk factor below is in addition to the risk factors previously disclosed in the Company’s annual report on Form 10-K for the fiscal year ended March 31, 2015.

### Our trading business is slowing.

The economic slowdown globally and specifically in China makes it difficult to predict demand. As we are seeing slower demand, lower margins, longer payment cycles, and larger companies downsizing and some exiting the market, we have begun to cut back on risk that could expose our balance sheet. Such a cut back inevitably will result in lower revenue to the point where we may have to exit the business rather than take on additional risk. However, the economic slowdown does not appear to be affecting the pace of deregulation or growth in the medical cannabinoid industry. We are pivoting away from higher-risk trading to becoming a leader in the emerging legal cannabinoid business by focusing on building infrastructure and building intellectual property in phytocannabinoid based therapies. If we exit the trading business we could have lower revenue and there is no guarantee that the capital markets will recognize our efforts in the phytocannabinoid industry and therefore our stock price could be adversely affected.

Filed Feb 16, 2016.
Source: SEC EDGAR, the filing index for accession 0001185185-16-003719. Last ingested by Listed: Nov 6, 2026, 16:27 ET. No prices; not investment advice.
